Type of non Hodgkin's lymphoma-Mantle cell lymphoma - Page 2 of 7 Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Mantle cell lymphoma Posts on Medivizor

Do stem cell transplants improve patients’ long-term survival?

Posted by on Apr 25, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the long-term survival of patients who received stem cell transplants (SCT) and compared them to the general population. The authors found that patients who received SCTs had almost the same chance of survival as the general population and identified factors that alter this chance. Some background Treatments such as...

Read More

Does immune cell boosting drug G-CSF reduce the effects of chemotherapy in different cancers?

Posted by on Apr 5, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effects of granulocyte colony-stimulating factor (G-CSF) given as a preventative measure in patients with high- and medium-risk cancer receiving chemotherapy. The results showed that preventative G-CSF allowed more patients to complete chemotherapy treatment and lowered patients’ chances of developing secondary...

Read More

Evaluating the R-BAC regimen for patients with MCL that stops responding to TKI therapy

Posted by on Feb 22, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of the R-BAC (rituximab, bendamustine, cytarabine) regimen for patients with relapsed or unresponsive mantle cell lymphoma (MCL). This study concluded that R-BAC was effective for these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL). After initial...

Read More

Evaluating Bendamustine-EAM conditioning chemotherapy for patients with mantle cell lymphoma

Posted by on Feb 5, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of bendamustine-EAM (Be-EAM) chemotherapy for patients with mantle cell lymphoma (MCL) before a stem cell transplant. This study found that this regimen improved survival outcomes compared to standard regimens. Some background Stem cell transplants (SCT) remain the standard of care for...

Read More

Evaluating high-dose cyclophosphamide for patients with hard-to-treat B-cell non-Hodgkin’s lymphoma

Posted by on Jan 12, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of high-dose cyclophosphamide (Cytoxan) for the treatment of relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that high-dose cyclophosphamide was safe and effective for these patients. Some background Chemotherapy regimens remain a standard treatment...

Read More

Trends in outcomes of allogeneic transplantation for elderly patients with non-Hodgkin lymphoma

Posted by on Dec 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of allogeneic stem cell transplants (allo-SCT) in elderly patients with non-Hodgkin’s lymphoma (NHL). This study found that allo-SCT has improved survival outcomes for these patients. Some background Allogeneic stem cell transplantation (allo-SCT) can be highly effective for patients with...

Read More

How effective and safe is acalabrutinib compared to other treatments for patients with mantle cell lymphoma?

Posted by on Nov 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness and safety of acalabrutinib (Calquence) to other targeted therapies for patients with mantle cell lymphoma (MCL). The authors found that acalabrutinib was just as safe and more effective for these patients. Some background MCL is a type of non-Hodgkin's lymphoma treated in...

Read More

What factors can predict the success of stem cell transplantation for patients with non-Hodgkin lymphoma?

Posted by on Nov 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the risk factors associated with delayed engraftment (DE) in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some background...

Read More

The effect of uric acid levels on the outcomes of patients having an allogeneic stem cell transplant

Posted by on Nov 2, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the association of uric acid levels before a stem cell transplant and patient outcomes. This study concluded that high uric acid levels before the transplant led to an increased mortality. Some background Uric acid is a product of metabolic breakdown and is a normal component of urine. It can also be...

Read More

Does stem cell transplantation affect the quality of life of older patients with NHL?

Posted by on Oct 10, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the quality of life reported by elderly patients with non-Hodgkin's lymphoma (NHL) after a stem cell transplant (SCT). The authors concluded that quality of life for these patients was very good following SCT. Some background Autologous SCT is the standard of care in first-line treatment for...

Read More